Metallothionein and Fas (CD95) are expressed in squamous cell carcinoma of the tongue

European Journal of Cancer

Volumn 33, Issue 11, 1997, Pages 1860-1864

  Sundelin, K ^a   Jadner, M ^a   Norberg Spaak, L ^a   Davidsson, A ^b   Hellquist, H B ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

Author keywords

Apoptosis; Bcl 2; Carcinoma squamous cell; Chelator; Fas; Metallothionein; Tongue

Indexed keywords

FAS ANTIGEN; METALLOTHIONEIN; PROTEIN BCL 2;

ADULT; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TONGUE CARCINOMA;

ANTIGENS, CD95; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; METALLOTHIONEIN; MIDDLE AGED; TONGUE NEOPLASMS;

EID: 0031424547     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00216-5     Document Type: Article

References (38)

1. Tsujimoto Y, Cossman J, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985, 228, 1440-1443.
2. Tsujimoto Y, Bashir MM, Givol I, Cossman J, Jaffe E, Croce CM. DNA rearrangements in human follicular lymphoma can involve the 5′ or the 3′ region of the bcl-2 gene. Proc NatlAcad Sei USA 1987, 84, 1329-1331.
3. Regueiro ÇA, Millân I, De la Torre A, et al. Influence of boost technique (external beam radiotherapy or brachytherapy) on the outcome of patients with carcinoma of the base of the tongue. Acta Oncol 1995, 34, 225-233.
4. Vaux DL, Cory S, Adams JM. The Bcl-2 gene promotes haematopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988, 335, 440-445.
5. Poster DG, Harrison LB, Strong EW, et al. Organ-function preservation in advanced oropharynx cancer: results with induction chemotherapy and radiation. J Clin Oncol 1995, 13, 671-680.
6. Nunez G, London G, Hockenbery D, Alexander M, McKearn J, Korsmeier SJ. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. JImmunol 1990, 144, 3602-3610.
7. Pilotti S, Collini P, Rilke F, Cattoretti G, Del Bo R, Pierotti MA. Bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J Pathol 1994, 172, 337-342.
8. Pezzella F, Turley H, Kuzu I, et al. bcl-2 protein in non-small cell lung carcinoma. N EnglJMed 1993, 329, 690-694.
9. Doglioni C, Dei Tos AP, Laurino L, Chiarelli C, Barabareshi M, Viale G. The prevalence of Bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. Virchows Arch 1994, 424, 47-51.
10. Kägi, JHR. Overview of metallothionein. Methods in Enzymology, 205. San Diego, Academic Press, 1991, 613-626.
11. van den Oord JJ, Sunardhi-Widaputra S, van Damme B, De Ley M. Monoclonal antibody to liver metallothionein: a novel marker for myoepithelial cells. Pathol Res Proa 1993, 189, 1187-1190.
12. Bier B, Douglas-Jones A, Tötsch M, et al. Immunohistochemical demonstration of metallothionein in normal human breast tissue and benign and malignant breast lesions. Breast Cancer Res Treat 1994, 30, 213-221.
13. Sunardhi-Widyaputra S, van Damme B. Immunohistochemical pattern of bcl-2 and PTHrP-positive cells in primary, in recurrent and in carcinoma in pleomorphic adenomas. Pathol Res Proa 1995, 191, 1186-1191.
14. Fresno M, Wu W, Rodriquez JM, Nadji M. Localization of metallothionein in breast carcinomas. An immunohistochemical study. Virchows Arch (A) 1993, 423, 215-219.
15. Schmid KW, Ellis IO, Gee JMW, et al. Presence and possible significance of imunocytochemically demonstrable metallothionein over-expression in primary invasive ductal carcinoma of the breast. Virchows Arch (A) 1993, 422, 153-159.
16. Oyama T, Take H, Hikino T, lino Y, Nakajima T. Immunohistochemical expression of metallthionein in invasive breast cancer in relation to proliferative activity, histology and prognosis. Oncology 1996, 53, 112-117.
17. Oishi M, Maeda K, Sugiyama S. Distribution of apoptosismediating Fas antigen in human skin and effects of anti-fas monoclonal antibody on human epidermal keratinocyte and squamous cell carcinoma cell lines. Arch Dermatol Res 1994, 286, 396-4107.
18. Firestein GS, Yeo M, Zwaifler NJ. Apoptosis in rheumatoid arthritis synovium. J Clin Invest 1995, 96, 1631-1638.
19. Aggarwal BB, Singh S, Lapushin RK, Totpal K. Fas antigen signals proliferation of normal human diploid fibroblast and its mechanism is different from tumor necrosis factor receptor. FEES 1995, 363, 5-8.
20. Koizumu H, Wakisaka M, Nakada K, et al. Demonstration of apoptosis in neuroblastoma and its relationship to tumour regression. Virchows Arch 1995, 427, 167-173.
21. Trauth BC, Klas C, Peters AMJ, et al. Monoclonal antibodymediated tumor regression by induction of apoptosis. Science 1989, 245, 301-305.
22. Yonehara S, Ishii A, Yonehara MA. Cell-killing monoclonal antibody (anti-fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989, 169, 1747-1756.
23. Itoh N, Yonehara S, Ishii A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991, 66, 233-243.
24. Itoh N, Nagata SA. A novel protein domain required for apoptosis. JBiol Chem 1993, 268, 10932-10937.
25. Tytor M. Clinical, histological and cytometrical findings in oral cavity carcinomas and their therapeutical and prognostic significance. Medical Dissertation, Bergen University, Asene Trykkeri as, Ulset, Norway, 1990.
26. Jasini B, Elmes ME. Immunohistochemical detection of metallothionein. In Riordan JF, Vallée BL, eds. Methods in Enzymology, 205. San Diego, Academic Press, 1991, 95-107.
27. Shi S-R, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991, 39, 741-748.
28. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear fragmentation. J Cell Biol 1992, 119, 493-501.
29. van den Oord ]J De Ley M. Distribution of metallothionein in normal and pathological human skin. Arch Dermatol Res 1994, 286, 62-68.
30. Bakhshi A, Jensen JP, Goldman P, et al. Cloning the chromosomal breakpoint of t(14, 18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 1985, 41, 899-906.
31. Cleary ML, Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Nail Acad Sei USA 1985, 82, 7439-7443.
32. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved honolog, Bax, that accelerates programmed cell death. Cell 1993, 74, 609-619.
33. Newport JW, Forbes DJ. The nucleus: structure, function, and dynamics. Annu Rev Biochem 1987, 56, 535-565.
34. Chen-Levy Z, Nourse J, Cleary ML. The bcl-2 candidate protooncogene product is a 24-kilodalton integral membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation. MolCeïïBiol 1989, 9, 701-710.
35. Hockenbery DM, Oltvai ZN, Yin X-M, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993, 75, 241-251.
36. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992, 52, 6940-6944.
37. Lu Q-L, Elia G, Lucas S, Alero Thomas J. Bcl-2 proto-oncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma. Int J Cancer 1993, 53, 29-35.
38. Hellquist HB, Sundelin K, Di Bacco A, Tytor M, Manzotti M, Viale G. Tumour growth fraction and apoptosis in salivary gland acinic cell carcinomas. Prognostic implications of Ki-67 and bcl-2 expression and of in situ end labelling (TUNEL). J Pathol 1997, 181, 323-329.